S&P 500   2,713.16 (+1.86%)
DOW   23,189.40 (+2.25%)
QQQ   198.85 (+1.21%)
FB   169.21 (+2.21%)
MSFT   164.70 (-0.34%)
GOOGL   1,193.55 (+0.88%)
AMZN   2,012.01 (+0.72%)
CGC   14.94 (+4.18%)
NVDA   265.09 (-1.23%)
BABA   198.55 (+1.07%)
MU   46.47 (-0.41%)
T   30.34 (+3.06%)
GILD   73.97 (-4.84%)
DIS   102.75 (+3.18%)
PRI   89.73 (+2.87%)
S&P 500   2,713.16 (+1.86%)
DOW   23,189.40 (+2.25%)
QQQ   198.85 (+1.21%)
FB   169.21 (+2.21%)
MSFT   164.70 (-0.34%)
GOOGL   1,193.55 (+0.88%)
AMZN   2,012.01 (+0.72%)
CGC   14.94 (+4.18%)
NVDA   265.09 (-1.23%)
BABA   198.55 (+1.07%)
MU   46.47 (-0.41%)
T   30.34 (+3.06%)
GILD   73.97 (-4.84%)
DIS   102.75 (+3.18%)
PRI   89.73 (+2.87%)
S&P 500   2,713.16 (+1.86%)
DOW   23,189.40 (+2.25%)
QQQ   198.85 (+1.21%)
FB   169.21 (+2.21%)
MSFT   164.70 (-0.34%)
GOOGL   1,193.55 (+0.88%)
AMZN   2,012.01 (+0.72%)
CGC   14.94 (+4.18%)
NVDA   265.09 (-1.23%)
BABA   198.55 (+1.07%)
MU   46.47 (-0.41%)
T   30.34 (+3.06%)
GILD   73.97 (-4.84%)
DIS   102.75 (+3.18%)
PRI   89.73 (+2.87%)
S&P 500   2,713.16 (+1.86%)
DOW   23,189.40 (+2.25%)
QQQ   198.85 (+1.21%)
FB   169.21 (+2.21%)
MSFT   164.70 (-0.34%)
GOOGL   1,193.55 (+0.88%)
AMZN   2,012.01 (+0.72%)
CGC   14.94 (+4.18%)
NVDA   265.09 (-1.23%)
BABA   198.55 (+1.07%)
MU   46.47 (-0.41%)
T   30.34 (+3.06%)
GILD   73.97 (-4.84%)
DIS   102.75 (+3.18%)
PRI   89.73 (+2.87%)
Log in

NASDAQ:CALACalithera Biosciences Stock Price, Forecast & News

$4.95
+0.21 (+4.43 %)
(As of 04/7/2020 10:37 AM ET)
Add
Compare
Today's Range
$4.79
Now: $4.95
$4.99
50-Day Range
$3.21
MA: $5.47
$7.80
52-Week Range
$2.45
Now: $4.95
$8.04
Volume88,876 shs
Average Volume664,972 shs
Market Capitalization$320.17 million
P/E RatioN/A
Dividend YieldN/A
Beta2.24
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor for the treatment of cystic fibrosis; and CB-708, an orally administered small molecule inhibitor of CD73. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Read More
Calithera Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.46 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CALA
CUSIPN/A
Phone650-870-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.25 million
Book Value$2.24 per share

Profitability

Net Income$-89,860,000.00

Miscellaneous

Employees79
Market Cap$320.17 million
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive CALA News and Ratings via Email

Sign-up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter.


Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions

How has Calithera Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Calithera Biosciences' stock was trading at $5.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CALA stock has decreased by 5.4% and is now trading at $4.95. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Calithera Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Calithera Biosciences.

When is Calithera Biosciences' next earnings date?

Calithera Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Calithera Biosciences.

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences Inc (NASDAQ:CALA) issued its quarterly earnings results on Wednesday, March, 11th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.02. View Calithera Biosciences' earnings history.

What price target have analysts set for CALA?

5 analysts have issued 12-month price objectives for Calithera Biosciences' stock. Their forecasts range from $6.00 to $7.00. On average, they anticipate Calithera Biosciences' share price to reach $6.67 in the next twelve months. This suggests a possible upside of 34.7% from the stock's current price. View analysts' price targets for Calithera Biosciences.

Has Calithera Biosciences been receiving favorable news coverage?

News coverage about CALA stock has trended very negative this week, according to InfoTrie. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Calithera Biosciences earned a news impact score of -3.3 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutCalithera Biosciences.

Are investors shorting Calithera Biosciences?

Calithera Biosciences saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 1,627,200 shares, an increase of 5.7% from the February 27th total of 1,540,000 shares. Based on an average daily trading volume, of 433,500 shares, the short-interest ratio is presently 3.8 days. Approximately 4.7% of the company's shares are sold short. View Calithera Biosciences' Current Options Chain.

Who are some of Calithera Biosciences' key competitors?

What other stocks do shareholders of Calithera Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Celadon Group (CGI), Dynavax Technologies (DVAX), First Solar (FSLR), Camtek (CAMT), Plug Power (PLUG) and United Continental (UAL).

Who are Calithera Biosciences' key executives?

Calithera Biosciences' management team includes the following people:
  • Dr. Susan M. Molineaux, Co-Founder, CEO, Pres & Director (Age 65)
  • Ms. Sumita Ray, Sr. VP, Gen. Counsel & Chief Compliance Officer (Age 45)
  • Dr. Keith Orford, Chief Medical Officer (Age 47)
  • Ms. Stephanie Wong, Sr. VP of Fin. & Sec. (Age 45)
  • Ms. Jennifer McNealey, VP of Investor Relations & Strategy

What is Calithera Biosciences' stock symbol?

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

How do I buy shares of Calithera Biosciences?

Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Calithera Biosciences' stock price today?

One share of CALA stock can currently be purchased for approximately $4.95.

How big of a company is Calithera Biosciences?

Calithera Biosciences has a market capitalization of $320.17 million and generates $22.25 million in revenue each year. The biotechnology company earns $-89,860,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. Calithera Biosciences employs 79 workers across the globe. View additional information about Calithera Biosciences.

What is Calithera Biosciences' official website?

The official website for Calithera Biosciences is http://www.calithera.com/.

How can I contact Calithera Biosciences?

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]

This page was last updated on 4/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel